Overview
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controls
Eligibility
Inclusion Criteria :
Common criteria for retrospective MS patients:
- Patients aged 18 years or older
- Clinical isolated syndrome (CIS) with or without dissemination in space
- Patients affiliated to an appropriate health insurance
Criteria for Aggressive MS group
• Start of a 2nd line therapy within the two years following the CIS
Criteria for Non aggressive MS group
- No conversion according to McDonald criteria from clinical isolated syndrome to multiple sclerosis within 2 years or
- Conversion based to McDonald criteria treated or not with first line disease modifying therapy within 2 years.
- Have a minimum of least 2 years of follow-up.
Healthy volunteers
- Aged 18 years or older
- No history of clinically isolated syndrome or MS
Pairing criteria :
- Age +/- 5 years
- Sex
Prospective MS Patients
- Patients aged 18 years or older
- Clinical isolated syndrome (CIS) with or without dissemination in space
- Patients affiliated to an appropriate health insurance
Exclusion Criteria :
- Ongoing participation to a another study
- Refusal to genetic analyses
- Immunosuppressive drug at the time of blood collection
- Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard)
- Pregnancy